血液腫瘤:多發性骨髓瘤(MM) - 早期徹底的診斷和新的治療選擇帶給疾病管理大幅影響的可能性
Hematological Malignancies: Multiple Myeloma (MM) - Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease
|出版日期||內容資訊||英文 82 Pages
|血液腫瘤:多發性骨髓瘤(MM) - 早期徹底的診斷和新的治療選擇帶給疾病管理大幅影響的可能性 Hematological Malignancies: Multiple Myeloma (MM) - Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease|
|出版日期: 2015年01月21日||內容資訊: 英文 82 Pages||
While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile?
Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues.
In this report, we highlight the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ.
Keywords: : Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma, RRMM, Newly Diagnosed Multiple Myeloma, NDMM, molecular diagnostics, FISH, next generation sequencing, Kyprolis, carfilzomib, POMALYST, pomalidomide, Velcade, bortezomib, Revlimid, lenalidomide, Panobinostat, Elotuzumab, Masivet, masitinib, Ixazomib, Aplidin, plitidepsin, Daratumumab, Imbruvica, ibrutinib, Imetelstat, Sylvant, siltuximab, ACE-011, sotatercept, Oprozomib, ARRY-520, filanesib, ALT-801, AT7519M, BT-062, Cabozantinib, Melflufen, KPT-330, selinexor, CT-011, pidilizumab, LymphoSIGHT, microRNAs, ExiLENTSYBR, CLIA-certified, Flow Cytometry, Immunohistochemistry, Illumina, DNA-based cancer diagnostics, Gene Expression Profiling, GEP, iPLEX Genotyping, MMprofiler, GeneChip